Podcast 19 Apr 2024
The biotech investment landscape in 2024
Dive into 2024’s biotech investment strategies with RTW Investments on our podcast. Discover trends shaping the landscape ahead.”
IPO
- Latest Posts
In Depth 8 Apr 2024
A wave of biotech layoffs: will the trend continue throughout 2024?
Thousands of jobs have been at risk over the past year due to mass layoffs by biotech companies across the globe.
In Depth 18 Mar 2024
Will the US biotech funding surge trigger a renaissance in the global biotech industry?
After a couple of challenging years in biotech investment, the US leads the march for recovery. Delve into the specifics driving this uptick.
News and Trends 8 Jan 2024
Is the biotech industry poised for recovery in 2024?
The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery.
In Depth 11 Sep 2023
Evolving biotech funding trends: VCs lead new series B deals, but early-stage deals require insider support
With biotech funding trends always evolving, HSBC Innovation Banking’s inaugural Venture Healthcare Report lays out the trends seen in the first half (1H) of 2023, where valuations underwent a necessary reset, and venture capitalists emerged from their cautious stance, eventually embarking on a fresh wave of investments. However, an overall decline in investment was still […]
News and Trends 21 Jan 2022
Two Gene Therapy Players Launch IPOs on Stormy Stock Market
After a drought of more than a year, the European gene therapy sector saw initial public offerings from Genenta Science and Genflow Biosciences. The firms aim to shine as biotech stocks elsewhere perform poorly. Until recently, European gene therapy companies were going through a dry spell in terms of launching initial public offerings (IPO). The […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 10 Nov 2021
Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks
German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the Nasdaq last week, fueling tentative hopes of renewed investor interest in biotech stocks after a rollercoaster year. The company downsized its initial IPO target of around €500M ($576M) by offering fewer shares than initially planned. This is widely seen as […]
News and Trends 15 Oct 2021
Third-Generation DNA Sequencing Shines with Oxford Nanopore’s IPO
Oxford Nanopore Technologies, until recently one of very few unicorns in the European biotech industry, had a stellar IPO on the London Stock Exchange late last month. This is ushering in a whole new generation of DNA sequencing, genetics research, and diagnostics. During the first day of the IPO, which bagged the firm over €400M […]
News and Trends 7 Oct 2021
Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts to use artificial intelligence to fuel drug discovery, with global tech investors often taking the lead. The Oxford, UK-based company Exscientia has one of the most mature artificial intelligence (AI)-focused drug discovery pipelines, alongside companies like BenevolentAI in the UK, […]
News and Trends 25 May 2021
Delayed IPOs and Market Drops Batter Biotech Stocks
Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […]
News and Trends 20 Apr 2021
Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market. Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics […]
News and Trends 31 Mar 2021
Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells
The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […]
ADVERTISEMENT